Key result
Treatment with erythrocyte membrane-camouflaged xanthohumol nanoparticles significantly reduced reactive oxygen species-dependent ferroptosis and improved doxorubicin-induced cardiac dysfunction.
Why the study?
Xanthohumol has potential to mitigate doxorubicin-induced cardiotoxicity, but poor water solubility and low biocompatibility severely restrict its in vivo application.
Does treatment with erythrocyte membrane-camouflaged xanthohumol nanoparticles prevent doxorubicin-induced cardiotoxicity in preclinical models?
Does treatment with erythrocyte membrane-camouflaged xanthohumol nanoparticles prevent doxorubicin-induced cardiotoxicity in preclinical models?
Erythrocyte membrane-camouflaged xanthohumol nanoparticles offer a promising biomimetic delivery system to mitigate doxorubicin-induced cardiotoxicity by inhibiting ferroptosis.
Preclinical biomimetic XH nanoparticles for DIC remain hypothesis-generating; prospective trials needed before clinical translation.
Doxorubicin (DOX) chemotherapy is a cornerstone of cancer treatment, but its clinical application and effectiveness are severely restricted due to its life-threatening cardiotoxicity. Xanthohumol (XH), a compound from traditional Chinese medicine, is noted for its antioxidant properties and the potential to mitigate DOX-induced cardiotoxicity (DIC). However, its poor water solubility results in low biocompatibility, making it susceptible to immune system clearance, which severely restricts its application in vivo. In this study, we first identified and demonstrated that XH can effectively mitigate DIC by inhibiting ferroptosis. We designed a biomimetic nanodelivery system encapsulating XH within porous poly(lactic- co -glycolic acid) (PLGA) nanoparticles, further coated with an erythrocyte membrane (XH-NPs@RBCm). This system offers several advantages, including evasion of macrophage phagocytosis and prolonged circulation time, thereby enhancing the stability and bioavailability of XH in vivo. Treatment with XH-NPs@RBCm significantly reduced reactive oxygen species-dependent ferroptosis, improving the DOX-induced myocardial atrophy and cardiac dysfunction. Our study underscores the therapeutic promise of XH-NPs@RBCm in treating DIC through ferroptosis inhibition, offering key insights into biomimetic nanodelivery system development for DIC management.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied Doxorubicin-induced cardiotoxicity. Erythrocyte membrane-camouflaged xanthohumol nanoparticles (XH-NPs@RBCm) was evaluated on Reactive oxygen species-dependent ferroptosis, myocardial atrophy, and cardiac dysfunction. Treatment with erythrocyte membrane-camouflaged xanthohumol nanoparticles significantly reduced reactive oxygen species-dependent ferroptosis and improved doxorubicin-induced cardiac dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: